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Results of large randomized trials have shown that survival rates after breast conserving surgery are equivalent to those obtained by radical
mastectomy. Breast conserving surgery with wide local excision in women with early stage breast cancer who are thought to have a single
and resectable tumour as determined by clinical examination and conventional imaging followed by postoperative irradiation is the standard
of care in early breast cancer. Mapping of local disease is the key element to guide optimal surgery to obtain tumour-free margins, thereby
decreasing risk of local recurrence. The usual preoperative workup of breast malignancy consists of clinical breast examination and
mammography with or without ultrasound. However, mammography and ultrasound fail to accurately assess tumour extent in as many as
a third of patients eligible for breast conserving therapy. It is well established that magnetic resonance imaging is far superior to
mammography (with and without ultrasound) for mapping the local extent of breast cancer. Experts advocate its use despite its high costs,
high number of false positive findings, and lack of evidence from randomized prospective trials and, notably, fear of ‘‘overtreatment.’’ This
article discusses the current role of breast magnetic resonance imaging with its clinical advantages and applications.Resume
Les resultats d’essais randomises d’envergure ont demontre que le taux de survie a la suite d’une chirurgie conservatrice du sein equivaut
a celui decoulant d’une mastectomie radicale. Chez les femmes ayant rec¸u un diagnostic de cancer du sein a un stade precoce et chez
lesquelles l’examen clinique et l’imagerie conventionnelle ont revele une tumeur jugee unique et resecable, la chirurgie conservatrice du sein
avec large excision locale suivie d’une irradiation postoperatoire representent le traitement habituel pour les cancers du sein au premier stade.
La localisation de la maladie est l’element cle d’une chirurgie optimale qui permet d’obtenir des marges exemptes de tissu tumoral, reduisant
ainsi les risques d’une recidive locale. L’evaluation preoperatoire habituelle d’une tumeur maligne du sein consiste en un examen mammaire
clinique et une mammographie avec ou sans echographie. Toutefois, jusqu’au tiers des patientes admissibles a une chirurgie conservatrice du
sein ne peuvent subir une evaluation exacte de l’ampleur de la tumeur au moyen de la mammographie et de l’echographie. Il est reconnu que
l’imagerie par resonance magnetique est de loin superieure a la mammographie (avec ou sans echographie) pour localiser et determiner
l’etendue locale du cancer du sein. Les specialistes en preconisent l’utilisation malgre les cou^ts eleves qui s’y rattachent, le grand nombre de
resultats faux-positifs ainsi que le manque d’elements probants dans les essais randomises prospectifs et, notamment, la peur du « traitement
excessif ». Cet article traite du ro^le actuel de l’imagerie par resonance magnetique du sein, de me^me que de ses avantages et applications
cliniques.
 2012 Canadian Association of Radiologists. All rights reserved.
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Adequate treatment of women with breast cancer relies on therapy (BCT). BCT consists of wide local excision of the
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Figure 1. (A) A 39-year-old lactating woman with a right palpable finding; dense mammogram with an ill-defined mass. (B) Ultrasound, showing an irregular,
suspicious mass. (C) Multifocal multicentric cancer (pathology: invasive ductal carcinoma with an extensive intraductal component).
Figure 2. Involvement of pectoralis muscle with pleural deposits (locally
advanced breast cancer).
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multicentric foci of disease results in higher local recurrence
rates and is a contraindication for BCT and hence preoper-
ative identification is important for appropriate treatment
[2,3]. The 5-year local-recurrence rate after BCT is about
5%, and it doubles if tumour is incompletely excised.
Complete gross excision of the tumour maximizes local
control, which, in turn, results in better survival [4,5].
Comparative studies of breast magnetic resonance
imaging (MRI) and conventional imaging with clinical
assessment show consistently that MRI has higher accuracy
for determining the extent of disease [6,7]. With remarkable
improvement in technique, preoperative MRI is now
detecting foci of disease otherwise occult to conventional
imaging with a high sensitivity of 94%-100% [8,9]. Docu-
mentation of higher tumour load often leads to an alteration
of management (wider excisions and more mastectomies),
thereby negating the results of several long-standing
randomized control trials, which have shown that outcomes
with BCT with breast irradiation are similar to those with
radical disfiguring surgery [10,11]. At the same time, the
very high negative predictive value of breast MRI helps to
predict the absence of breast cancer in the same or the
contralateral breast with a very high confidence (99.6%) and
can be used to justify a more focused therapeutic approach
(eg, partial breast irradiation) or avoid prophylactic contra-
lateral mastectomy [12]. It also can help convert a possible
ipsilateral mastectomy into a lumpectomy in women with
very dense breasts on mammography.
In this article, we will review the utilisation of preoper-
ative breast MRI and its impact on management in:
 Ipsilateral tumour mapping,
 Assessment of the contralateral breast,
 Patients undergoing neoadjuvant therapy, and
 Preoperative assessment of residual tumour.
We will also briefly highlight the shortcomings of MRI in
preoperative imaging.Ipsilateral Tumour Mapping
The term preoperative staging is a misleading term,
because this ‘‘stage’’ is different from the stage as specified
by the American Joint Committee on Cancer. Hence,
preoperative mapping is a better term [13]. The International
Consensus Consortium II [14] recommends by using an
overall size of the lesion (which includes both the in situ and
the invasive components of the tumour) and a prognostic size
of the tumour, which indicates the invasive component. The
overall size is mapping because it pertains to local recurrence
rates, and the prognostic size relates to stage and systemic
recurrence rates.
Results of studies reveal that MRI is the best method for
depicting overall size and multifocal and multicentric ipsi-
lateral disease [15]. Multifocality is defined as satellite lesions
located within the same quadrant as the index lesion, whereas
multicentric disease is defined as a separate focus of cancer
Figure 3. (A) Left breast mass; heterogeous dense breast tissue with interstitial oedema. (B) Ultrasound, showing irregular suspicious mass. (C) Magnetic
resonance image, showing a large tumour mass, with multifocal and multicentric disease. (D) Multicentric disease (pathology: invasive ductal carcinoma with
high-grade ductal carcinoma in situ).
Figure 4. (A) Palpable left inferior quadrant mass; history of radiation for gastric lymphoma that involved the left lower chest wall; dense breast tissue; no
definite abnormality. (B) Ultrasound, showing a mass with malignant morphology. (C) Magnetic resonance imaging, showing multifocal and multicentric
tumour nodules. (D) Pathology: invasive ductal carcinoma with extensive intraductal component.
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Figure 5. (A) Postmantle radiation, with a palpable mass seen on mammography. (B, C) Ducts distended with soft-tissue mass confirmed on biopsy to be
intermediate-grade ductal carcinoma in situ. (D) Magnetic resonance imaging, showing very minimal to no enhancement in inferior quadrant.
Figure 6. A 55-year-old womanwhowas a BRCA2mutation carrier with prior
left lumpectomy. Preoperative magnetic resonance imaging (MRI) before
prophylactic bilateral mastectomy revealed enhancing lesion in right breast
otherwise occult. MRI biopsy showed high-grade ductal carcinoma in situ.
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extended to another quadrant through a discontinuous growth
pattern (Figure 1) [13] . Meta-analysis of 19 observational
studies that consists of 2610 women showed additional foci of
disease in 16%, of which 66% were malignant on histology.
Incremental MRI-only detection varies between approxi-
mately 1% and 28% formultifocal cancer and between 2% and
15% for multicentric cancer [16], which parallels what is
known from landmark histologic studies.
The additional foci diagnosed by breast MRI have the same
size and the same histology as the cancers detected by
conventional imaging. They, however, do exhibit a higher
nuclear grading [15] and are associated with a higher biologic
aggressiveness [12]. The MRI findings of additional foci of
cancer coupled with the findings at the index lesion have
impacted surgical therapy in women with breast cancer. A
pooled study of 12 studies with more than 1908 women
showed that MRI impacted planning in 15%-27% as improved
selection of BCT, decreased surgical procedures with tumour-
free margins, and detection of contralateral cancer; 11.3% had
more extensive surgery than initially planned; 8.1% BCT
eligible converted to mastectomy for MRI only lesions; and
5.5% had more extensive surgery due to false-positive find-
ings on MRI [13,16]. High sensitivity of MRI also results in
significant false-positive findings, which may necessitate
further imaging, needle biopsy, or surgical biopsy [17].
The contraindications to BCT are nipple involvement,
chest-wall invasion (Figure 2), inadequate lesion to breast
size ratio, and larger than clinically evident size of mass and
extensive intraductal component (EIC) of ductal carcinoma
in situ (DCIS) surrounding the invasive component These
contraindications are best assessed with MRI than other
conventional imaging techniques.
Preoperative breast MRI has been particularly useful in
the following subgroup of women: Women with heterogeneously dense breast tissue
(Figure 3).
 Women with EIC of DCIS surrounding the invasive
component, seen in 30%-40% of all invasive breast
carcinomas. EIC occult to conventional imaging is
a frequently encountered problem is women with invasive
ductal carcinoma and DCIS, and is the most important
treatment-related risk factor for recurrent disease. These
patients will need a second surgical procedure; a consid-
erable number of these patients end up requiring
mastectomies [18]. High-resolution, high-contrast breast
MRI accurately depicts DCIS and better demonstrates the
extent of disease than mammography (Figure 4). The
reported sensitivity of MRI for DCIS has ranged from
77%-96% [19]. False underestimation may occur in
Figure 7. A 46-year-old woman, left biopsy-proven multifocal invasive ductal
carcinoma (IDC). Magnetic resonance imaging (MRI), showing enhancing
lesion in the right breast, which was localized under MRI guidance;
pathology: 0.6-cm IDC surrounded by 2.5-cm DCIS.
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estimation may occur due to benign proliferative
pathology (Figure 5) [20].
 Women with the notoriously difficult to image invasive
lobular carcinoma (ILC). Studies show that additional
ipsilateral lesions were noted in 32% of cases only with
MRI and an additional 7% showed contralateral lesions.
Surgical management changed in 28%, of which 88%
were found necessary based on pathology. Preoperative
breast MRI in women with ILC would reduce BCT
failure and re-excisions [21].
 High-risk women with breast cancer are likely to benefit
from staging MRI because the rate of multifocal and
multicentric disease is as high as 45%-50% [22].Figure 8. (A) A 51-year-old woman with right biopsy-proven invasive ductal carc
IDC. Younger women with lesion with irregular margins on
mammography and a size discrepancy of 10 mm between
mammography and ultrasonography have added utility of
preoperative MRI [23].
 Women selected for accelerated partial-breast irradiation
(APBI) and intraoperative radiation therapy (IORT).
Traditionally, when a separate cancer, occult to conven-
tional imaging, is present in the same breast (multicentric
focus), BCT would involve excision of the index lesion,
with clear margins that leave behind the undetected
multicentric focus, which would be taken care of by the
whole breast irradiation (WBI). Over the past several
years, there has been growing interest in the use of APBI
and IORT as an alternative to WBI. APBI and IORT offer
decreased overall treatment time and may allow
a decrease in the radiation dose delivered to uninvolved
portions of the breast and adjacent organs [24]. Detection
of additional foci of disease is of critical importance in
patients selected for APBI and IORT because these
multicentric foci do not get irradiated.
Contralateral Breast Cancer
Women with diagnosed unilateral breast cancer have
a 5 times higher risk of developing contralateral synchronous
or metachronous breast cancer than the general population
[25]. Numerous risk factors have been implicated for
development of bilateral breast cancer: nulliparity; younger
age at first breast carcinoma; lobular histology; and multi-
centricity of first carcinoma and family history, that is,
women with a first-degree relative with early age onset breast
carcinoma and BRCA mutations (40 times more risk at
10 years) (Figure 6) [26] have a higher risk of developing
bilateral breast cancer. In addition, young women treated
with irradiation for postpartum mastitis, Hodgkin disease,
and tuberculosis also are at an increased risk.
The prevalence of synchronous cancer is 1%-3% and that
of metachronous cancer is 5%-7%. MRI detects synchronous,
contralateral breast cancer that is not detected clinically orinoma (IDC). (B) Left enhancing lesion; magnetic resonance imaging biopsy,
Figure 10. Excision for invasive ductal carcinoma referred for magnetic
resonance imaging after pathology reports of positive surgical margins;
residual tumour was seen around surgical cavity, with extension into the
nipple.
Figure 9. (A) Biopsy-proven invasive ductal carcinoma: Preneoadjuvant therapy. (B) After neoadjuvant therapy, showing shrinkage of mass with residual
tumour tissue (partial response).
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(Figure 7). The ACRIN (American College of Radiology
Imaging Network) trial 6667 found that MRI detected mam-
mographically and clinically occult cancers in the contralat-
eral breast with a sensitivity of 91% and a specificity of 88%.
The negative predictive value of MRI was 99% [27]. The
histology for the contralateral malignancies is DCIS in
approximately 35% and invasive cancer in 65% [28]. Early
detection of in situ or node-negative invasive disease in the
contralateral breast can lead to simultaneous treatment of
synchronous cancers rather than multiple treatments on
separate occasions (Figure 8).
Monitoring Preoperative Neoadjuvant Treatment
Systemic chemotherapy is known to improve survival
for patients with invasive breast cancer and is considered
the standard of care for patients who are node positive with
large primary tumours and for many patients with high-risk,
node-negative disease. A number of trials have compared
preoperative chemotherapy with postoperative chemotherapy.
Although, there was no difference in disease-free survival and
overall survival, more women who received preoperative
chemotherapy were able to undergo breast conservation.
These findings have led to the increased use of preoperative or
neoadjuvant chemotherapy. The National Surgical Adjuvant
Breast and Bowel Project B-18 and other studies have
demonstrated that response of the primary tumour to treat-
ment, as measured clinically or by histopathology, is associ-
ated with both disease-free and overall survival. Thus,
preoperative chemotherapy allows the opportunity to monitor
the primary tumour response.
MRI in women on neoadjuvant treatment is used for the
initial determination of extent of disease for proper staging,
early identification of poor responders, and identification
of the presence, and accurately demonstrates the extent of
residual disease before definitive surgery. MRI is more reli-
able than the conventional methods in the assessment of
tumour size and vascularity changes during and after
chemotherapy. The addition of advanced imaging techniques,such as magnetic resonance spectroscopy, to further charac-
terize tumour cellularity, and metabolic features appears
promising (Figure 9) [29].
Preoperative MRI Before Re-excision
Residual tumour after excisional biopsy has been reported
in 32%-63% of cases of breast cancer. The sensitivity,
specificity, and accuracy of MRI in showing the presence and
extent of residual disease is 61.2%, 69.7%, and 64.6%,
respectively [30]. MRI before re-excision can detect addi-
tional foci of multifocal or multicentric and contralateral
tumour occult to conventional imaging, which, if detected,
could change surgical management provided histologic
corelation can be established (Figure 10).
Figure 11. (A) A 45-year-old woman with an axillary mass, which was biopsied and revealed invasive ductal carcinoma (IDC). (B) Magnetic resonance
imaging (MRI), showing a second lesion, which underwent MRI wire localization. Pathology, 0.8-cm IDC surrounded by 4.5-cm ductal carcinoma in situ (not
seen on MRI); the patient had completion mastectomy.
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excisional biopsy, differentiating contrast enhancement due
to residual cancer from postsurgical inflammatory change is
difficult. Benign postoperative enhancement usually is thin
and rim-like around the seroma cavity. Any enhancement
that appears nodular or irregular would need additional
workup. The time interval between lumpectomy and MRI
influences the specificity of MRI, with the greatest specificity
of 75% being achieved when MRI is performed between
28 and 35 postoperative days [31].
Conclusion
In summarizing the available data, in comparison with
conventional imaging, breast MRI increases the detection of
tumour foci in addition to the known index lesion within the
ipsilateral breast and synchronous tumour in the contralateral
breast, which has significant impact on surgical planning,
particularly in the specific subgroups of women previously
described. With such a high-detection rate comes the
controversy of the high number of false positives, which may
lead to overtreatment. Results of studies show that addition
of MRI to preoperative workup causes more-extensive
surgery, additional utilisation of resources, and delay in
surgery, with no impact in overall survival benefit (Figure 11)
[32]. The recently published COMICE (Comparative Effec-
tiveness of MRI in Breast Cancer) trial negates the impact of
MRI on the re-excision rates in women with preoperative
MRI compared with those with no preoperative MRI [33].
However, this study commenced during the time when there
was an absence of accurate MRI-guided interventions. Their
cases had extremely wide surgical margins, and the impact of
MRI in such cases may not be significant. However, in
institutes where surgical techniques aim at removal of
smaller resection volumes, the impact of MRI can be
significant in reducing re-operation rates [34].
Despite the lack of randomized trials to show survival
benefit or improved surgical outcome (re-excision and
recurrence rates) and the additional workup of false posi-
tives, MRI is a modality of significant clinical impact, whichleads us to the exciting era of APBR and IORT. MRI has
been shown to reduce the positive margin rate in women with
ILCs without increasing mastectomy rates [34]. The high
staging accuracy of breast MRI makes it an attractive method
for assessing tumour distribution and for measuring response
to preoperative chemotherapy. In centres with expertise in
MRI interpretation and intervention, it can be a phenomenal
adjunctive tool for patient care. The high negative predictive
value of MRI might reduce the number of unnecessary
mastectomies and allay patient anxiety. Preoperative MRI
should be interpreted by taking into account clinical breast
examination, mammography, and sonography, and does not
replace a good traditional workup of lesions. All findings that
would impact surgical planning should be worked up and
verified with image-guided biopsy, and this would potentially
reduce the chances of overtreatment due to MRI-only find-
ings [35]. Centres that run a breast MRI program should
ensure proper equipment and imaging technique, and provide
training necessary to achieve high-quality breast MRI, and
should have the ability to perform MRI-guided biopsy or
needle localization for MRI only detected lesions. All
workups should be completed within a time frame of
a maximum 1 month to avoid surgical delay.
As radiologists, our job is to give maximum information
with appropriate workup. Women newly diagnosed with
breast cancer should always be informed of the potential risks
and benefits of preoperative MRI. The MRI-only lesions
cannot be ignored. Evolving understanding of these subclin-
ical MRI-only lesions and improvement of MRI intervention
will pave the way for MRI-guided lumpectomies, which
allows breast conservation. A multidisciplinary approach
should be instituted to address any changes in management
that result from preoperative MRI, thus providing appropriate
care and allaying women’s and their physicians’ anxieties
regarding overtreatment of women with breast cancer.
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